Compare · CLDI vs RVMD
CLDI vs RVMD
Side-by-side comparison of Calidi Biotherapeutics Inc. (CLDI) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDI and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.88B, about 14099.2x CLDI ($2.9M).
- Over the past year, CLDI is down 95.7% and RVMD is up 338.2% - RVMD leads by 433.8 points.
- RVMD has been more active in the news (20 items in the past 4 weeks vs 4 for CLDI).
- RVMD has more recent analyst coverage (25 ratings vs 2 for CLDI).
- Company
- Calidi Biotherapeutics Inc.
- Revolution Medicines Inc.
- Price
- $1.09-1.80%
- $190.64-1.21%
- Market cap
- $2.9M
- $40.88B
- 1M return
- -21.01%
- -9.89%
- 1Y return
- -95.69%
- +338.15%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 4
- 20
- Recent ratings
- 2
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest CLDI
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events
- SEC Form 424B5 filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form 4 filed by Chief Financial Officer Jackson Andrew C.
- SEC Form 4 filed by Chief Scientific Officer Fernandez Santidrian Antonio
- SEC Form 4 filed by Director Schoeneck James A
- SEC Form 4 filed by Director Leftwich Scott
- SEC Form 4 filed by Director Stewart Alan R.
- SEC Form 4 filed by Director Peoples George
Latest RVMD
- Officer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)
- Chief Development Officer Sandler Alan B. sold $67,941 worth of shares (341 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 52,868 units (SEC Form 4) to satisfy withholding tax
- Officer Mancini Anthony sold $353,449 worth of shares (1,774 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,116 units (SEC Form 4) (for tax liability)
- Officer Kelsey Stephen Michael sold $1,109,554 worth of shares (5,569 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 286,307 units (SEC Form 4) to satisfy withholding obligation
- Chief Operating Officer Horn Margaret A sold $989,613 worth of shares (4,967 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 149,680 units (SEC Form 4) (withholding tax)
- Officer Goldsmith Mark A sold $2,786,938 worth of shares (13,988 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 253,342 units (SEC Form 4) (for withholding tax)
- SVP & General Counsel Cislini Jeff sold $670,631 worth of shares (3,366 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,541 units (SEC Form 4) (tax liability)
- Chief Financial Officer Anders Jack sold $807,513 worth of shares (4,053 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 119,216 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.